Menu Back toSession-8-ABSTRACT-SESSION

Pharmacovigilance and Risk Management Strategies Conference

NEW! The 2019 meeting will be a full three days, allowing maximum learning opportunities!


Session Chair(s)

Lisa Melanie Harinstein, PharmD

Lisa Melanie Harinstein, PharmD

  • Team Leader, Division of Pharmacovigilance, FDA
  • FDA, United States
For the first time at the DIA Pharmacovigilance and Risk Management Strategies Conference, this new session will feature four presentations selected from an abstract submission process. This session will explore the innovative use of pharmacoepidemiology studies, real world evidence, social media, and signal management tools in pharmacovigilance.


Ruben  Ayzin Rosoky, MD, PhD

Ruben Ayzin Rosoky, MD, PhD

  • Sr Safety Physician
  • United Biosource Corp., France
Michael  Forstner, PhD

The European IV Iron PASS Consortium: Experiences from Coordinating a Multi-Company, Multi-Registry PASS

Michael Forstner, PhD

  • Head of Clinical and Patient Safety
  • Biogen BBU, Switzerland
Jennifer B Hannan, MS

Innovative Pharmacovigilance (PV) Solution in Social Media: Compliance, Signaling, and Social Media Footprint

Jennifer B Hannan, MS

  • Director, Pharmacovigilance Business Liaison
  • Merck & Co., Inc., United States
Sanjeev  Miglani, MD

Evaluation of Different Signal Management Tools: New Regulatory Perspectives

Sanjeev Miglani, MD

  • Founder and Director
  • AWINSA Life Sciences, United States
Irene  Cosmatos, MS

The Value of RWD in Safety Signal Refinement

Irene Cosmatos, MS

  • Senior Research Specialist, Database Analytics Automation
  • UBC, United States